Abstract
In metastatic cancer studies, the deterioration of the patient’s health status is often observed during the trial either because of the toxicity of treatment or the progression of disease. This deterioration is very likely to be reflected in the patient’s quality of life. Therefore, when analyzing the global health status/quality-of-life (QL) score of the EORTC QLQ-C30 instrument, an event, QL deterioration can be defined in terms of health states. Deterioration could be characterized by an absorbing state (similar to death when analyzing survival time). We define only two kinds of events, so repeated measures of QL are easily converted into time-to-event data, and the Kaplan-Meier method and log-rank tests can be used for analysis. We apply this methodology to data from a clinical trial of treatments for metastatic colorectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, H., Fleishman, S.B., De Hues, J.C.J.M., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P.B, Schraub, S., Sneeuw, K., Sullivan, M. and Takeda, F. for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 85, 365–376.
Beitz, J., Gnecco, C. and Justice, R. (1998). Quality-of-life end points in cancer clinical trials: the US Food and Drug Administration Perspective. Journal of the National Cancer Institute Monographs 20, 7–9.
Billot, L. and Mesbah, M. (1999). “Analyse d’un essai de Qualité de Vie longitudinal en cancérologie avec prise en compte des abondans” in Actes des Journées Vannes-Bordeaux. (Proceedings).
Cole, B.F. and Kilbridge, K.L. (2002). Quality-adjusted survival analysis in cancer clinical trials. In: Mesbah, M., Cole, B.F. and Lee, M.L.T. (eds.), Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis, Boston: Kluwer.
Cox, D.R., Fitzpatrick, R., Fletcher, A.E., Gore, S.M., Spiegelhalter, D.J. and Jones, D.R. (1992). Quality-of-life assessment: can we keep it simple? Journal of the Royal Statistical Society, Series A 155, 353–393.
Cunningham, D., Pyrhönen, S., James, R.D., Punt, C.J.A., Hickizsh, T.P., Heikkila, R., Johannesen, T.B., Starkhammar, H., Topham, C.A., Awad, L., Jacques, C. and Herait, P. (1998) Randomised trial of iritonecan plus supportive care versus supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352, 1413–1418.
Douillard, J.Y., Cunningham, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L. and Rougier, P. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355, 1041–1047.
Dupuy, J.F. (2002) Joint modeling of survival and nonignorable missing longitudinal quality of life data. In: Mesbah, M., Cole, B.F. and Lee, M.L.T. (eds.), Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis, Boston: Kluwer.
Dupuy, J.F. and Mesbah, M. (2002). Joint modeling of event time and nonignorable missing longitudinal data. Lifetime Data Analysis (to appear).
Fayers, P., Aaronson, N., Bjordal K., Curran, D. and Groenvold, M. for the EORTC Quality of Life Study Group (1999). EORTC QLQ-C30 Scoring Manual, 2nd Edition. Brussels: European Organization for Research and Treatment of Cancer.
Heutte, N. and Huber-Carol, C. (2002). Semi-Markov models for quality of life data with censoring. In: Mesbah, M., Cole, B.F. and Lee, M.L.T. (eds.), Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis, Boston: Kluwer.
McLachlan, S.A., Devins, G.M. and Goodwin P.J. (1998). Validation of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (QLQ-C30) as a measure of psychological function in breast cancer patients. European Journal of Cancer 34, 510–517.
Osoba, D. (1994). Lessons learned from measuring health-related quality of life in oncology. Journal of Clinical Oncology 12, 608–616.
Rougier, P., van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P. and Jacques, C. (1998). Randomized trial of iritonecan versus fluoracil by continuous infusion after fluoracil failure in patients with metastatic colorectal cancer. Lancet 352, 1407–1412.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Awad, L., Zuber, E., Mesbah, M. (2002). Applying Survival Data Methodology to Analyze Longitudinal Quality of Life Data. In: Mesbah, M., Cole, B.F., Lee, ML.T. (eds) Statistical Methods for Quality of Life Studies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3625-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3625-0_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5207-3
Online ISBN: 978-1-4757-3625-0
eBook Packages: Springer Book Archive